ResMed (RMD) FY2025 10-K Annual Report
ResMed (RMD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Aug 8, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ResMed FY2025 10-K Analysis
Business Overview
- • Core business model: Design, manufacture, and distribute medical devices for respiratory care and sleep apnea management
- • Emphasis on enhanced cybersecurity governance with CISO-led program and annual board updates on risk landscape and incident response
- • Strategic focus on robust cybersecurity risk management involving cross-functional oversight teams for compliance and incident mitigation
- • CISO with 20+ years’ experience, including prior CISO roles at Mattel and Universal Music Group, strengthening security leadership
- • Detailed cybersecurity protocols and governance highlighted, reflecting increased priority on protecting information systems in fiscal 2025
Management Discussion & Analysis
- • Revenue split into Sleep and Breathing Health and Residential Care Software segments; revenue recognized on shipment and service provision respectively
- • Rebates, discounts, and credits reduce Sleep and Breathing Health revenue, estimated via historical data and sales targets quarterly or annually
- • Deferred revenue arises from extended warranties, monitoring data, software access, and maintenance, recognized over one to five years
- • No significant financing components in contracts; returns historically infrequent and insignificant, revenue adjusted accordingly
- • Revenue allocation based on standalone selling prices when multiple performance obligations exist in contracts
Risk Factors
- • Delaware corporate law provisions enable issuance of 2.0 million preferred shares without stockholder approval
- • Charter anti-takeover provisions potentially delaying beneficial management changes or acquisition offers
- • Risk of preferred stock issuance diluting common stock voting rights and depressing market price
ResMed FY2025 Key Financial MetricsXBRL
Revenue
$5.1B
▲ +9.8% YoY
Net Income
$1.4B
▲ +37.2% YoY
Gross Margin
59.4%
▲ +269bp YoY
Operating Margin
32.7%
▲ +458bp YoY
Net Margin
27.2%
▲ +543bp YoY
ROE
23.5%
▲ +248bp YoY
Total Assets
$8.2B
▲ +18.9% YoY
EPS (Diluted)
$9.51
▲ +37.4% YoY
Operating Cash Flow
$1.8B
▲ +25.0% YoY
Source: XBRL data from ResMed FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ResMed
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.